Danish diabetes giant Novo Nordisk (NOV: N) has announced results from the Phase III STEP HFpEF trial of semaglutide.
Compared with placebo, a 2.4mg dose of the GLP-1 agonist led to significant reductions in heart failure-related symptoms and physical limitations.
There were also improvements in exercise function and greater weight loss for adults with heart failure with preserved ejection fraction (HFpEF) and obesity.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze